Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Cash: 2021-2024

Historic Change in Cash for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$92.1 million.

  • Amylyx Pharmaceuticals' Change in Cash rose 6934.50% to $166.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.9 million, marking a year-over-year increase of 343.84%. This contributed to the annual value of -$92.1 million for FY2024, which is 185.52% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Change in Cash of -$92.1 million as of FY2024, which was down 185.52% from $107.7 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Cash registered a high of $107.7 million during FY2023, and its lowest value of -$92.1 million during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Change in Cash had a median value of $12.9 million in 2022 and averaged $9.5 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Change in Cash surged by 736.96% in 2023 and then crashed by 185.52% in 2024.
  • Amylyx Pharmaceuticals' Change in Cash (Yearly) stood at $37.3 million in 2021, then crashed by 65.52% to $12.9 million in 2022, then soared by 736.96% to $107.7 million in 2023, then crashed by 185.52% to -$92.1 million in 2024.